FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

New findings suggest asthma may be reversible in some cases, offering hope for long-term remission and a shift in treatment ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA Ph: +1-203-852-6800, 800-243-6002 ...

Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

Pulmonologists alarmed by climate-linked asthma surge, find hope in novel medications: Nandita Vijayasimha, Bengaluru Tuesday, May 6, 2025, 08:00 Hrs [IST] Pulmonologists associat ...

In April 2025, Areteia Therapeutics announced a study will assess the efficacy and safety of dexpramipexole as an adjunctive ...

Sanofi to showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions at ATS conference: Paris Saturday, May 3, 2025, 16:00 Hrs [IST] ...

Tofacitinib, a Janus kinase (JAK) inhibitor drug, used either as a standalone treatment or alongside other drugs to address ...

Healthcare professionals typically prescribe these drugs to treat eczema, though older 2018 research established dupilumab as an effective asthma treatment as well. More recently, researchers have ...

Protein levels are presented in pg/ml. Biologics targeting T2-driven immune responses, including dupilumab (anti-IL-4Rα monoclonal antibody), represent a significant advancement in the management of ...